Man Successfully Kept Alive with Pig Kidney for 271 Days Until He Could Receive a Human One

In a pioneering medical advancement, a genetically modified pig kidney has successfully functioned within a human patient for an unprecedented duration of 271 days. This significant achievement was reported by a team of surgeons at Massachusetts General Hospital, who conducted the groundbreaking procedure on Tim Andrews, a 66-year-old recipient. The operation, performed in January 2025, is being hailed as a vital step forward in xenotransplantation—the transplantation of organs from one species to another.

Tim Andrews was in urgent need of a kidney transplant due to end-stage renal failure. Reflecting on his decision to participate in this experimental surgery, he remarked, “I was dying. I figured, if I’m going to die, I might as well do something for humanity and be part of this experiment.” His willingness to take part in such a pioneering study has underscored the vital role patient cooperation plays in advancing medical research.

The genetically engineered pig kidney functioned effectively for six months before it began to fail, at which point surgeons removed the organ. Following a brief period of dialysis, Andrews successfully underwent another transplantation in January 2026, receiving a human kidney from a matched donor. This transition from the genetically modified organ to a human kidney marked a significant milestone in organ transplantation procedures.

The findings of this remarkable case were published on 3rd September in The Lancet, providing the medical community with invaluable insights into the potential of xenotransplantation. Dr. Leonardo Riella, the lead author of the paper and medical director for kidney transplantation at Mass General Brigham, highlighted the pressing organ shortage crisis in transplantation. “The organ shortage is the greatest crisis we have right now in transplantation,” he stated.

According to Riella, xenotransplantation could serve as a crucial solution to bridge the gap created by the insufficient availability of human organs. He commented, “We know that the best treatment option for patients with end-stage kidney disease is transplantation, but we simply don’t have enough human organs to transplant in a timely manner.” The hope is that these pig kidneys could support patients in urgent need, allowing them to go off dialysis while waiting for compatible human donors.

Medical professionals believe that, as safety and durability are further established, xenotransplantation could also evolve beyond merely serving as a temporary solution, potentially functioning as a viable long-term treatment option for kidney failure. This perspective opens the door to a future where genetically modified organs might provide more sustainable solutions to persistent organ shortages.

The significance of this development extends beyond the direct medical implications; it speaks volumes about the courage and commitment of patients who choose to participate in experimental treatments. Riella emphasised the importance of patient participation in pioneering medical studies, stating, “The patients are the true pioneers here. By stepping forward and being willing to participate in these early-stage studies, they are advancing the science.”

The outcome of Tim Andrews’s journey holds promise for future advancements in xenotransplantation and organ transplantation more broadly. As the medical field grapples with the ongoing organ shortage crisis, innovations such as these offer hope to many patients who are awaiting life-saving transplants.

This case of xenotransplantation not only reflects the potential for improved outcomes for patients in need of organ transplants but also sets a precedent for further research in this exciting field of medicine. Looking ahead, the lessons learned from Andrews’s experience could very well shape the future of organ transplantation, addressing both immediate and long-term challenges within the healthcare sector.